Cilostazol Tablets

PharmAlliance International Labs introduces Cilostazol Tablets, a groundbreaking innovation in platelet aggregation inhibition. Available in 50mg and 100mg strengths, these tablets offer relief for conditions like intermittent claudication and peripheral arterial disease. Administered orally twice daily, adherence to prescribed dosages is vital for optimal efficacy. While generally well-tolerated, transient side effects like headache and diarrhea may occur. With its potent pharmacodynamic action, Cilostazol enhances blood flow and circulation, improving patient outcomes. Experience the transformative potential of Cilostazol Tablets from PharmAlliance International Labs, committed to empowering individuals on their path to optimal health.



PharmAlliance International Labs: Revolutionizing Healthcare with Cilostazol Tablets

Company Introduction:

Welcome to PharmAlliance International Labs Private Limited, a beacon of excellence and innovation in the pharmaceutical landscape. We are dedicated to elevating global health standards and enhancing the well-being of individuals worldwide. With unwavering commitment and cutting-edge research, we proudly present our latest breakthrough – Cilostazol Tablets, poised to redefine treatment paradigms and improve patient outcomes.

Drug Classification:

Cilostazol Tablets epitomize the pinnacle of pharmaceutical innovation, belonging to the esteemed class of platelet aggregation inhibitors. By selectively inhibiting specific enzymes within the body, these tablets thwart the aggregation of platelets, thereby preventing the formation of blood clots. This mechanism of action translates into improved blood flow and circulation, particularly in the lower extremities, offering relief and restoration to those in need.


Crafted with precision and efficacy in mind, our Cilostazol Tablets are available in two strengths – 50mg and 100mg, encapsulated in easy-to-swallow oral formulations. Each tablet is meticulously packaged in blister packs containing 30 tablets, ensuring optimal freshness and potency for every dose.


The therapeutic spectrum of Cilostazol Tablets extends across a diverse array of medical conditions, including intermittent claudication, peripheral arterial disease (PAD), and the prevention of secondary stroke. Whether alleviating the debilitating symptoms of intermittent claudication or enhancing walking distance in patients with PAD, these tablets stand as steadfast allies in the pursuit of optimal health and vitality.


Administration of Cilostazol Tablets is simple and straightforward, typically prescribed for oral intake twice daily, preferably with a one-hour gap before or two hours after meals. Adherence to prescribed dosages and schedules is paramount to ensure therapeutic efficacy and mitigate the risk of adverse events. Patients are advised against abrupt discontinuation of Cilostazol without consulting their healthcare provider to avoid exacerbation of symptoms.


The recommended starting dose of Cilostazol is 100mg twice daily, with dosage adjustments guided by individual patient response and tolerability. Special consideration is warranted for elderly patients or those with hepatic or renal impairment, who may require tailored dosage regimens to optimize therapeutic outcomes.


Following oral administration, Cilostazol is swiftly absorbed into the bloodstream, reaching peak plasma concentrations within 2-3 hours. Extensive hepatic metabolism via the cytochrome P450 enzyme system ensues, culminating in the formation of active metabolites. With an elimination half-life of approximately 11-13 hours, Cilostazol ensures sustained pharmacological effects and enduring relief for patients.


The pharmacodynamic prowess of Cilostazol hinges upon its ability to inhibit phosphodiesterase III (PDE3) enzymes, resulting in heightened levels of cyclic adenosine monophosphate (cAMP) within platelets and blood vessels. Elevated cAMP levels impede platelet aggregation and thrombus formation while promoting vasodilation, thereby augmenting blood flow and circulation to affected areas.

Side Effects:

While generally well-tolerated, Cilostazol may elicit transient side effects such as headache, diarrhea, palpitations, dizziness, and abnormal stools. While severe or persistent adverse events are rare, vigilant monitoring and prompt reporting to healthcare providers are imperative to ensure timely intervention and management.

Experience the Transformative Potential of Cilostazol Tablets from PharmAlliance International Labs. With a steadfast commitment to quality, safety, and efficacy, we endeavor to empower individuals on their journey to optimal health and well-being. For more information on Cilostazol Tablets and our comprehensive portfolio of pharmaceutical solutions, please visit our website or consult your healthcare provider.


There are no reviews yet.

Be the first to review “Cilostazol Tablets”

Your email address will not be published. Required fields are marked *© 2024. All rights reserved. Terms of use and Privacy Policy